SABS

SAB Biotherapeutics, Inc. (SABS) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies. The company's lead candidate, SAB-142, is a disease-modifying immunotherapy for autoimmune Type 1 Diabetes (T1D). As of the reporting date, SAB-142 is in a registrational Phase 2b clinical trial (SAFEGUARD study).

Key Financial Metrics

Note: The company has no revenue. Interest income for the six months ended June 30, 2026, was $2.756 million, driven by higher investment balances.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 140.2% for the three months ended June 30, 2026, compared to the same period in 2025. This was driven by a 131.1% increase in Research and Development (R&D) expenses and a 163.4% increase in General and Administrative (G&A) expenses.
• R&D Drivers: The increase in R&D costs is primarily due to clinical trial expenses and headcount growth supporting the Phase 2b SAFEGUARD study for SAB-142.
• Net Loss: Net loss for the three months ended June 30, 2026, was $(22.5) million, a 122.4% increase from $(10.1) million in the prior year period.
• Capital Structure: The company completed a March 2026 Public Offering, raising approximately $88.7 million in net proceeds. Additionally, in July 2025, a Series B Offering generated $175.0 million in gross proceeds.
• Investments: Total investments (short-term and long-term) increased significantly to approximately $199.7 million as of June 30, 2026, compared to $133.0 million at December 31, 2025.

Guidance, Outlook, and Risks

• Liquidity: Management states that existing resources are sufficient to cover operating cash needs for at least the twelve months following the report date. The company anticipates continuing losses as it funds product development and clinical trials.
• Clinical Progress: The SAFEGUARD Part A dose-ranging study completed enrollment in Q1 2026. Part B is actively enrolling. In July 2026 (subsequent event), Breakthrough T1D awarded a grant for the PRISE-hATG Phase 3 study, with SAB Biotherapeutics co-funding up to $1.4 million initially.
• Manufacturing: Construction began in Q2 2026 on a second farm facility in South Dakota to increase manufacturing capacity. A Master Manufacturing Services Agreement was signed with Emergent BioSolutions Canada Inc. in April 2026, with a minimum aggregate spend of $36.0 million following FDA approval.
• Risks: The company faces risks related to the success of clinical trials, regulatory approval, and the need for additional capital. It is classified as an "emerging growth company" and maintains a 100% valuation allowance on deferred tax assets.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $208 million in cash and investments against the accelerating burn rate (operating cash used was $24.1 million for the six months ended June 30, 2026).
• Warrant Liability Volatility: Monitor the fair value of warrant liabilities ($7.2 million), which fluctuate with stock price and volatility, impacting net loss.
• Clinical Milestones: Track enrollment and topline data for the SAFEGUARD Phase 2b trial and the subsequent PRISE-hATG Phase 3 study.
• Manufacturing Commitments: Review the financial impact of the $36 million minimum spend commitment with Emergent BioSolutions upon FDA approval.
• Dilution: Assess the impact of outstanding warrants (including Enrollment Date and Release Date Warrants) and options on future share count.